热门资讯> 正文
Forte Biosciences GAAP每股收益为-0.16美元
2024-05-14 05:16
- Forte Biosciences press release (NASDAQ:FBRX): Q1 GAAP EPS of -$0.16.
- Research and development expenses were $4.4 million for the three months ended March 31, 2024, compared to $4.8 million for the same period in 2023.
More on Forte Biosciences
- Seeking Alpha’s Quant Rating on Forte Biosciences
- Historical earnings data for Forte Biosciences
- Financial information for Forte Biosciences
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
